Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 15/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5908733 | 0.87 | ALDH1A1 (0.51) | FFAR1CA1CA2FFAR4LMNA | |
| SCHEMBL1907464 | 0.87 | PRMT1 (0.46) | FFAR1CA1CA2FFAR4LMNA | |
| SCHEMBL2257211 | 0.84 | F2RL1 (0.46) | FFAR1LMNA | |
| SCHEMBL6941010 | 0.84 | PPARA (0.51) | CA1CA2 | |
| SCHEMBL4461203 | 0.83 | CA2 (0.47) | CA2LMNASRD5A2 | |
| SCHEMBL19143369 | 0.83 | FFAR1 (0.59) | FFAR1CA1CA2FFAR4LMNA | |
| SCHEMBL17847695 | 0.82 | CA2 (0.46) | CA1CA2 | |
| SCHEMBL17834378 | 0.82 | PPARA (0.41) | FFAR1CA1CA2LMNAL3MBTL1 | |
| SCHEMBL4074491 | 0.81 | FFAR1 (0.57) | FFAR1CA1CA2FFAR4LMNA | |
| SCHEMBL584599 | 0.79 | FFAR1 (0.64) | FFAR1FFAR4LMNAL3MBTL1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | KYOWA HAKKO KOGYO CO.,LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| EP-1726584-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | AGTR2, ABL1, AGTR1 | FFAR1 651/4885CA1 4343/4885CA2 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.